INSIGHTS ON DOWNSTREAM MANUFACTURING

  • Accelerating Antibody Drug Development

    Learn more about the CaptureSelect antibody subdomain-specific affinity resins and how they address the purification challenges in therapeutic antibody development.

  • Upgrade Your Monoclonal Antibody Purification Workflow

    Learn about a new Protein A resin specifically designed to help improve your antibody purification process and featuring high capacity and a highly cross-linked agarose backbone.

  • The Dynamic Regulatory Environment Of Drug-Device Combination Products

    Examine the dynamic regulatory environment of drug-device combination products and provides concrete steps to take to navigate regulatory complexities and decrease time to market.

  • Achieving mRNA-LNP Delivery Beyond the Liver

    What are the most promising R&D efforts or recent developments in the space that are paving the way for extra-hepatic delivery?

    The rapid development, scale-up, and successful commercialization of mRNA vaccines served as a great case study on the important role mRNA/RNA therapeutics can play in society. However, for those striving to develop next-gen RNA therapeutics, achieving more specifically targeted non-viral delivery is a large hurdle to broadening these therapeutics’ applicability, durability, and effectiveness.

  • Overcoming Regulatory, Safety/Efficacy, and Toxicity Hurdles
    11/28/2022

    What are the biggest challenges the mRNA/RNA therapeutics field is struggling with in development today — and are we focused on solving the right challenges?  

    The rapid development, scale-up, and successful commercialization of mRNA vaccines served as a great case study on the important role mRNA/RNA therapeutics can play in society. However, for those striving to develop next-gen RNA therapeutics, achieving more specifically targeted non-viral delivery is a large hurdle to broadening these therapeutics’ applicability, durability, and effectiveness.

  • Q&A on LNP Cell-Specific Delivery
    11/28/2022

    What advancements have been made that have or can pave the way for more cell-specific delivery?  

    The rapid development, scale-up, and successful commercialization of mRNA vaccines served as a great case study on the important role mRNA/RNA therapeutics can play in society. However, for those striving to develop next-gen RNA therapeutics, achieving more specifically targeted non-viral delivery is a large hurdle to broadening these therapeutics’ applicability, durability, and effectiveness.

  • Defining A “Next-Gen” LNP
    11/28/2022

    How can we define a “next-generation” LNP?

    The rapid development, scale-up, and successful commercialization of mRNA vaccines served as a great case study on the important role mRNA/RNA therapeutics can play in society. However, for those striving to develop next-gen RNA therapeutics, achieving more specifically targeted non-viral delivery is a large hurdle to broadening these therapeutics’ applicability, durability, and effectiveness.

  • Q&A on Formulation & Stability of LNPs
    11/28/2022

    How does formulation impact the stability of LNPs and/or the RNA drug product?

    The rapid development, scale-up, and successful commercialization of mRNA vaccines served as a great case study on the important role mRNA/RNA therapeutics can play in society. However, for those striving to develop next-gen RNA therapeutics, achieving more specifically targeted non-viral delivery is a large hurdle to broadening these therapeutics’ applicability, durability, and effectiveness.

  • mRNA’s Future Beyond The COVID Vaccines
    11/28/2022

    What learnings can mRNA/RNA therapeutics makers take away from the successes of the mRNA COVID vaccines and Alnylam’s Onpattro, the first LNP-delivered antisense oligonucleotide?

    The rapid development, scale-up, and successful commercialization of mRNA vaccines served as a great case study on the important role mRNA/RNA therapeutics can play in society. However, for those striving to develop next-gen RNA therapeutics, achieving more specifically targeted non-viral delivery is a large hurdle to broadening these therapeutics’ applicability, durability, and effectiveness.

DOWNSTREAM MANUFACTURING SOLUTIONS